Abstract 170P
Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary hepatic malignancy considered to be a variant of hepatocellular carcinoma. It accounts for about ≈ 1-5% of all HCCs .Surgery (resection/liver transplantation) is the current standard treatment and remains the only potentially curative treatment option ; however, the role of chemotherapy is still controversial . Therefore, we conducted this study to evaluate the efficacy of chemotherapy in improving the survival of patients with Fibrolamellar hepatocellular carcinoma (FL-HCC).
Methods
Using SEER database, we extracted the data of 100 patients with FL-HCC from 2004 to 2014. There were 40 (40%) patients underwent surgery combined with chemotherapy, while 60(60%) of them received chemotherapy only. Patients’ demographics and staging system were assessed.
Results
Patients with FL-HCC had better outcomes when they received surgery alone compared to those who received surgery combined with chemotherapy, where overall 1-year relative survival rates were 98.3% and 95%, respectively (significant p value of 0.031).Subgroup analysis revealed that there is a highly significant P-value (< 0.0001) regarding both different age groups and staging system. On the other hand ;there is No significance for the p value was reported to the race or sex.Table:
170P
Variables | Survival of Patients | p value | |
---|---|---|---|
surgery combined with chemotherapy | Surgery alone | ||
Sex Male Female | 92.3% 100% | 100% 95.7% | 0.246 |
Age 0-19 20-39 40-59 60-79 | 100% 84.6% 100% 100%** | 100% 100% 100% 81.8% | <0.0001*** |
Race White Black Asian or Pacific Islander | 96.7% 100%** 85.7% | 98% 100% * | 0.838 |
staging I II IIIA IIIB IIIC IV | 100% 100%** 100% 100%** 100% 85.7% | 96.4% 100% 100% 100%** 100% 100% | <0.0001*** |
Highly significant P-value < 0.0001.
**few patients reported.
*NO recorded patients.
Conclusions
surgery alone without chemotherapy in patients with FL-HCC shows higher 1-year relative survival rates when compared to surgery combined with chemotherapy. So, we recommend surgery alone without chemotherapy as a superior modality for better survival. Further studies should be conducted on a larger number of patients to confirm the results. Keywords: Fibrolamellar hepatocellular carcinoma (FL-HCC), chemotherapy, surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yasmine Ashraf Mohamed Ali.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract